Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — H1 FY2023 Earnings Presentation
18 slides from Genetic Signatures's earnings presentation, Mar 14, 2023
Slide 1: 1H FY23 Market Update
For personal use only 1H FY23 Market Update March 2023
Slide 2: Disclaimer
1H1H FY23 FY23 MARKET MarketUPDATE Update Disclaimer March 2023 This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release. It comprises written For personal use only materials/slides for a verbal presenta
Slide 3: Investment highlights
Investment highlights 1H1H FY23 FY23 MARKET MarketUPDATE Update March 2023 Proprietary 3base® technology platform - a revolutionary approach for For personal use only molecular diagnostics Dramatically simplifies multiple pathogen testing from a single sample (multiplexing); more informative—simpler
Slide 4: Company Snapshot
1H1H FY23 FY23 MARKET MarketUPDATE Update Company Snapshot March 2023 For personal use only Financial information Share price (13-Mar-23) A$0.79 Shares on issue 143.4m Market capitalisation A$113.3m Cash (31-Dec-22) A$26.8m Debt (31-Dec-22) Nil Enterprise value A$86.5m Top shareholders % Asia Union
Slide 5: How 3base simplifies molecular targets
1H1H FY23 FY23 MARKET MarketUPDATE Update How 3base® simplifies molecular targets March 2023 For personal use only Molecular diagnostic tests are based on DNA/RNA sequences • DNA/RNA is unique to each organism. Genetic Signatures 3base® makes multiplex testing easier: • More informative – detect rel
Slide 6: 3base simplifies Syndromic Testing – EasyScreen Kits
3base® simplifies Syndromic Testing – EasyScreen™ Kits 1H1H FY23 FY23 MARKET MarketUPDATE Update March 2023 For personal use only Syndromic testing: simultaneously test for multiple pathogens that all can cause the same signs and symptoms • Respiratory infections: cough, runny nose, sore throat, hea
Slide 7: Strong underlying growth in core revenue streams
Strong underlying growth in core revenue streams 1H1H FY23 FY23 MARKET MarketUPDATE Update March 2023 Sales Revenue (A$m) 1H FY23 sales $10.4 million For personal use only • Anticipated material decline in pathogen-specific molecular testing for SARS-CoV-2 experienced across the industry • Replaced
Slide 8: Robust underlying growth though pandemic
Robust underlying growth though pandemic 1H1H FY23 FY23 MARKET MarketUPDATE Update March 2023 Sales Revenue (A$m) Covid “sugar hit” For personal use only • Revenues in FY21 & FY22 were significantly boosted by Pandemic sales Covid molecular test sales during pandemic • Inevitable decline in sales of
Slide 9: Revenue dominated by sale of syndromic tests
Revenue dominated by sale of syndromic tests 1H1H FY23 FY23 MARKET MarketUPDATE Update March 2023 Sales mix returning to syndromic tests focus For personal use only Sales Revenue (A$m) • Ensured company continued to build sales of syndromic tests throughout pandemic while benefitting from Covid oppo
Slide 10: Financial Summary – 1H FY23 Profit & Loss
Financial Summary – 1H FY23 Profit & Loss 1H1H FY23 FY23 MARKET MarketUPDATE Update March 2023 Investing in the future For personal use only A'000s 1H FY23 1H FY22 Sales revenue 10,405 21,838 Peak COVID testing in 1H FY22 Cost of materials (3,759) (6,283) 1H FY23 includes a prov. for stock write dow
Slide 11: Robust pipeline with multiple products cleared for sale
Robust pipeline with multiple products cleared for sale 1H1H FY23 FY23 MARKET MarketUPDATE Update March 2023 For personal use only DEVELOPMENT RESEARCH USE REGISTRATION TGA CE Mark FDA planned in progress (expect 2023) Converting to new protocol planned planned In development 11
Slide 12: Enteric Protozoan kit will provide entry to North America
Enteric Protozoan kit will provide entry to North America 1H1H FY23 FY23 MARKET MarketUPDATE Update March 2023 High need for Enteric Protozoan Kit For personal use only • 5.5 million tests conducted in the US pa • Primarily culture/microscopy: slow, labour intensive, unreliable • Detects leading pro
Slide 13: US 510(k) for Enteric Protozoan filing by end of April
US 510(k) for Enteric Protozoan filing by end of April 1H1H FY23 FY23 MARKET MarketUPDATE Update March 2023 For personal use only Final steps underway • Recruitment for trial involving 1,500 clinical samples was completed in July 2022 • For the several assays in GSS’s Enteric Protozoan Kit that were
Slide 14: Second product in clinical testing to support US FDA filing
Second product in clinical testing to support US FDA filing 1H1H FY23 FY23 MARKET MarketUPDATE Update March 2023 For personal use only Next product • Multi-pathogen syndromic test • Significant benefits from 3base® technology for this application • Easier trial as all targets are in a predicate devi
Slide 15: Business development activity in overseas markets
Business development activity in overseas markets 1H1H FY23 FY23 MARKET MarketUPDATE Update March 2023 Key appointments For personal use only • Distributor Channel Manager – Europe • Regulatory Affairs Associate – Europe • Head of Clinical Operations – North America New distributors pending • Israel
Slide 16: Growth initiatives
Growth initiatives 1H1H FY23 FY23 MARKET MarketUPDATE Update March 2023 Leverage experience in AU market to grow international sales For personal use only • Europe – drive adoption of other 3base® products • US – build 3base® franchise once Protozoan Detection Kit is cleared Build & expand portfolio
Slide 17: Upcoming milestones
Upcoming milestones – 12 months 1H1H FY23 FY23 MARKET MarketUPDATE Update March 2023 For personal use only US Enteric Protozoan Kit • 510(k) filing April 2023 • Launch product once clearance is granted Increase sales and presence in UK and European markets • Contracts with new customers • Direct sal
Slide 18: Contact Us
For personal use only Contact Us Dr John Melki Genetic Signatures Ltd Chief Executive Officer E: john.melki@geneticsignatures.com P: +61 (0)2 9870 7580 Visit us www.geneticsignatures.com Follow us 18